In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

In Vivo's Deals Of The Month, January 2018

Executive Summary

In Vivo's editors pick January's most significant deals, including an alliance of players new to health care and Celgene's big buys. (Free article.)

 

Top Alliance: Amazon, JP Morgan And Berkshire Hathaway's JV

Details are scarce about the partners' plans to improve health care and reduce its cost for their US employees, yet markets shuddered at the news of this alliance. Considering the rumblings about [Amazon.com Inc.]'s move into health care and the collective clout of these three companies, one might anticipate an impact that reaches beyond their employee base.

 

Top Financing: BeiGene's FOPO

In a month that saw several notable follow-on public offerings, BeiGene (Beijing) Co. Ltd.'s stood out. The Beijing-based immuno-oncology developer netted $758 million through the sale of 7.9 million American Depositary Shares. Funds will go toward regulatory filings in China for its leading PD-1 and BTK inhibitors as well as business development and R&D. [See Deal]

 

Top M&A: Celgene Spends $10 Billion For Juno And Impact

We might have picked Sanofi's acquisitions of Ablynx NV and Bioverativ Inc., but in the end we opted for Celgene Corp.'s Juno Therapeutics Inc. and Impact Biomedicines buys. The $9 billion it paid for Juno gives Celgene full ownership of a pipeline of CAR-T therapies . Celgene paid $1.1 billion up front to acquire Impact and its sole candidate fedratinib, a selective JAK2 kinase inhibitor in Phase III for treatment-naïve myelofibrosis. [See Deal][See Deal]

 

 

 

Related Content

Topics

Related Companies

Related Deals

Latest News
See All
UsernamePublicRestriction

Register

IV005280

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel